Cue Biopharma to present at FOCIS 2023 annual meeting

Cue Biopharma announced that it will deliver an oral presentation on its Immuno-STAT platform and biologics as well as a poster on the company’s bispecific protein, CUE-401, for the treatment of autoimmune and inflammatory diseases at the Federation of Clinical Immunology Societies, FOCIS, 2023 Annual Meeting, being held June 20-23, 2023 in Boston, Massachusetts. Oral Presentation: Title: Immuno-STAT Platform: TCR-selective Engagers for Selective Targeting of IL-2 to Tumor-Specific T Cells. Dr. Quayle will describe the company’s CUE-100 series of Immuno-STAT biologics, designed to enable selective targeting of the immunostimulant cytokine interleukin-2 to tumor specific T cells for enhanced efficacy and safety profiles. Proof of concept for this platform has been achieved with clinical data from CUE-101, the company’s lead candidate. The data has demonstrated anti-cancer efficacy with a favorable tolerability profile and supports potential registrational paths for both CUE-101 as a monotherapy in third line recurrent/metastatic human papillomavirus 16+ head and neck squamous cell carcinoma, and CUE-101 in combination with KEYTRUDA in first line R/M HPV16+ HNSCC. Additionally, Dr. Quayle will discuss the modularity of the Immuno-STAT platform, which has enabled rapid generation of additional Immuno-STAT candidates targeting other tumor antigens, such as mutated KRAS or Wilms’ Tumor 1. Poster Presentation: Title: CUE-401: A Novel IL-2/TGF-beta Fusion Protein for the Induction of CD4+ FOXP3+ Regulatory T Cells. Cue Biopharma’s collaborator, Dr. DiPaolo, will discuss in vitro and in vivo data demonstrating the potential of CUE-401, the company’s novel bispecific protein designed to induce and expand regulatory T cells for the treatment of T-cell mediated autoimmune and inflammatory diseases.